Raman micro-spectroscopy monitors acquired resistance to targeted cancer therapy at the cellular level

Monitoring the drug efficacy or resistance in vitro is usually carried out by measuring the response of single few proteins. However, observation of single proteins instead of an integral cell response may lead to results that are not consistent with patient’s response to a drug. We present a Raman spectroscopic method that detects the integral cell response to drugs such as tyrosine kinase inhibitors (TKIs). Non-small cell lung cancer (NSCLC) patients with EGFR mutations develop acquired resistance to first (erlotinib)- and third (osimertinib)-generation TKIs. Large erlotinib-induced differences were detected by Raman micro-spectroscopy in NSCLC cells without T790M EGFR mutation but not in cells with this mutation. Additionally, Raman difference spectra detected the response of NSCLC cells with T790M EGFR mutation to second- (neratinib) and third-generation (osimertinib) TKIs, and the resistance of cells with T790M/C797S EGFR mutation to osimertinib. Thus, the in vitro Raman results indicated that NSCLC cells with T790M and T790M/C797S EGFR mutations are resistant to erlotinib- and osimertinib, respectively, consistent with the observed responses of patients. This study shows the potential of Raman micro-spectroscopy to monitor drug resistance and opens a new door to in vitro companion diagnostics for screening personalized therapies.

[1]  M. Cameron,et al.  Metabolism considerations for kinase inhibitors in cancer treatment , 2010, Expert opinion on drug metabolism & toxicology.

[2]  A. Walz,et al.  Model-based assessment of erlotinib effect in vitro measured by real-time cell analysis , 2015, Journal of Pharmacokinetics and Pharmacodynamics.

[3]  Hesham K. Yosef,et al.  Label-Free Raman Spectroscopic Imaging Monitors the Integral Physiologically Relevant Drug Responses in Cancer Cells. , 2015, Analytical chemistry.

[4]  H. Varmus,et al.  Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain , 2005, PLoS medicine.

[5]  M. Meyerson,et al.  The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP , 2008, Proceedings of the National Academy of Sciences.

[6]  Christian Matthäus,et al.  Label-Free Molecular Imaging of Biological Cells and Tissues by Linear and Nonlinear Raman Spectroscopic Approaches. , 2017, Angewandte Chemie.

[7]  Hugh J. Byrne,et al.  Comparison of subcellular responses for the evaluation and prediction of the chemotherapeutic response to cisplatin in lung adenocarcinoma using Raman spectroscopy. , 2011, The Analyst.

[8]  Juswinder Singh,et al.  Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. , 2013, Cancer discovery.

[9]  Gavin Jell,et al.  In vitro toxicology evaluation of pharmaceuticals using Raman micro‐spectroscopy , 2006, Journal of cellular biochemistry.

[10]  Daniel Niedieker,et al.  Colocalization of fluorescence and Raman microscopic images for the identification of subcellular compartments: a validation study. , 2015, The Analyst.

[11]  Jin-jian Lu,et al.  Characterization of osimertinib (AZD9291)-resistant non-small cell lung cancer NCI-H1975/OSIR cell line , 2016, Oncotarget.

[12]  Martina Havenith,et al.  Label-free imaging of metal-carbonyl complexes in live cells by Raman microspectroscopy. , 2010, Angewandte Chemie.

[13]  Jürgen Popp,et al.  High-Throughput Screening Raman Spectroscopy Platform for Label-Free Cellomics. , 2017, Analytical chemistry.

[14]  D. Schuppan,et al.  Erlotinib induces cell cycle arrest and apoptosis in hepatocellular cancer cells and enhances chemosensitivity towards cytostatics. , 2005, Journal of hepatology.

[15]  J. Baselga.  The EGFR as a target for anticancer therapy--focus on cetuximab. , 2001, European journal of cancer.

[16]  M. Buyse,et al.  Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. , 2016, The Lancet. Oncology.

[17]  H. Barr,et al.  Raman spectroscopy for identification of epithelial cancers. , 2004, Faraday discussions.

[18]  Lu Wei,et al.  Live-cell imaging of alkyne-tagged small biomolecules by stimulated Raman scattering , 2014, Nature Methods.

[19]  S. Digumarthy,et al.  Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors , 2011, Science Translational Medicine.

[20]  Axel Mosig,et al.  Label-free imaging of drug distribution and metabolism in colon cancer cells by Raman microscopy. , 2014, The Analyst.

[21]  M. Lee,et al.  Stimulated Raman scattering microscopy: an emerging tool for drug discovery , 2016, Chemical Society reviews.

[22]  Max Diem,et al.  Vibrational Spectroscopy for Medical Diagnosis , 2008 .

[23]  L. Sequist,et al.  The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies , 2015, Clinical Cancer Research.

[24]  P. Johnston,et al.  Molecular mechanisms of drug resistance , 2005, The Journal of pathology.

[25]  J. Baselga,et al.  Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  D. Planchard,et al.  Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First Line , 2017, Front. Med..

[27]  Hesham K. Yosef,et al.  Noninvasive Diagnosis of High-Grade Urothelial Carcinoma in Urine by Raman Spectral Imaging. , 2017, Analytical chemistry.

[28]  Chao Zhang,et al.  RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF , 2010, Nature.

[29]  J. Blenis,et al.  The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. , 2011, Trends in biochemical sciences.

[30]  A. Rehemtulla,et al.  Differential protein stability of EGFR mutants determines responsiveness to tyrosine kinase inhibitors , 2016, Oncotarget.

[31]  J. Popp,et al.  Raman Based Molecular Imaging and Analytics: A Magic Bullet for Biomedical Applications!? , 2016, Analytical chemistry.

[32]  J. Schlessinger,et al.  Cell Signaling by Receptor Tyrosine Kinases , 2000, Cell.

[33]  Lihua Shao,et al.  Erlotinib directly inhibits HER2 kinase activation and downstream signaling events in intact cells lacking epidermal growth factor receptor expression. , 2007, Cancer research.

[34]  Jin-jian Lu,et al.  Osimertinib induces autophagy and apoptosis via reactive oxygen species generation in non‐small cell lung cancer cells , 2017, Toxicology and applied pharmacology.

[35]  Daniel A. Haber,et al.  Epidermal growth factor receptor mutations in lung cancer , 2007, Nature Reviews Cancer.

[36]  Reiner Salzer,et al.  Infrared and Raman spectroscopic imaging , 2009 .

[37]  Alan S. Futran,et al.  ERK as a Model for Systems Biology of Enzyme Kinetics in Cells , 2013, Current Biology.

[38]  C. Paweletz,et al.  Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  Franck Bonnier,et al.  Doxorubicin Kinetics and Effects on Lung Cancer Cell Lines Using In-vitro Raman Micro-Spectroscopy: Binding Signatures, Drug Resistance and DNA Repair , 2019 .

[40]  C. Waltz.  Validation study. , 1988, NLN publications.

[41]  Chia-Chi Lin,et al.  Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  M. Peeters,et al.  Anti-epidermal growth factor receptor monotherapy in the treatment of metastatic colorectal cancer: where are we today? , 2009, The oncologist.

[43]  John R. Engen,et al.  Novel mutant-selective EGFR kinase inhibitors against EGFR T790M , 2009, Nature.

[44]  Sascha D Krauß,et al.  Integrating spatial, morphological, and textural information for improved cell type differentiation using Raman microscopy , 2018 .

[45]  Nick Stone,et al.  Spectropathology for the next generation: quo vadis? , 2015, The Analyst.

[46]  E. Olejniczak,et al.  Approach for targeting Ras with small molecules that activate SOS-mediated nucleotide exchange , 2014, Proceedings of the National Academy of Sciences.

[47]  Sanjeev Kumar,et al.  Vitamin A as an enzyme that catalyzes the reduction of MTT to formazan by vitamin C , 2000, Journal of cellular biochemistry.

[48]  R. Hamid,et al.  Comparison of alamar blue and MTT assays for high through-put screening. , 2004, Toxicology in vitro : an international journal published in association with BIBRA.

[49]  Axel Mosig,et al.  Spectral histopathology of colon cancer tissue sections by Raman imaging with 532 nm excitation provides label free annotation of lymphocytes, erythrocytes and proliferating nuclei of cancer cells. , 2013, The Analyst.

[50]  Aleksandra Markovets,et al.  Acquired EGFR C797S mediates resistance to AZD9291 in advanced non-small cell lung cancer harboring EGFR T790M , 2015, Nature Medicine.

[51]  J. Schlessinger,et al.  Signaling by Receptor Tyrosine Kinases , 1993 .

[52]  Y. Yarden,et al.  Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.

[53]  Han Liu,et al.  Neratinib induces ErbB2 ubiquitylation and endocytic degradation via HSP90 dissociation in breast cancer cells. , 2016, Cancer letters.

[54]  J. Schellens,et al.  Liquid chromatography-tandem mass spectrometric assay for the T790M mutant EGFR inhibitor osimertinib (AZD9291) in human plasma. , 2016, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[55]  N. Boku,et al.  Safety, efficacy and pharmacokinetics of neratinib (HKI-272) in Japanese patients with advanced solid tumors: a Phase 1 dose-escalation study. , 2012, Japanese journal of clinical oncology.

[56]  R. Doebele,et al.  A framework for understanding and targeting residual disease in oncogene-driven solid cancers , 2016, Nature Medicine.

[57]  Ramaswamy Nilakantan,et al.  Antitumor Activity of HKI-272, an Orally Active, Irreversible Inhibitor of the HER-2 Tyrosine Kinase , 2004, Cancer Research.

[58]  Dan Fu,et al.  Imaging the Intracellular Distribution of Tyrosine Kinase Inhibitors in Living Cells with Quantitative Hyperspectral Stimulated Raman Scattering , 2014, Nature chemistry.

[59]  Guillermo Repetto,et al.  Neutral red uptake assay for the estimation of cell viability/cytotoxicity , 2008, Nature Protocols.

[60]  Axel Mosig,et al.  Automated identification of subcellular organelles by coherent anti-stokes Raman scattering. , 2014, Biophysical journal.

[61]  Thomas R Huser,et al.  Raman spectroscopy and microscopy of individual cells and cellular components , 2008 .

[62]  Hesham K. Yosef,et al.  Raman Microspectroscopic Evidence for the Metabolism of a Tyrosine Kinase Inhibitor, Neratinib, in Cancer Cells , 2018, Angewandte Chemie.

[63]  K. Gerwert,et al.  Raman fiber-optical method for colon cancer detection: Cross-validation and outlier identification approach. , 2017, Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy.

[64]  M. Meyerson,et al.  EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. , 2005, The New England journal of medicine.

[65]  K. Gerwert,et al.  Virtual staining of colon cancer tissue by label-free Raman micro-spectroscopy. , 2017, The Analyst.

[66]  Patricia L. Harris,et al.  Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[67]  Ming-Sound Tsao,et al.  A review of erlotinib and its clinical use , 2006, Expert opinion on pharmacotherapy.

[68]  Cees Otto,et al.  Raman microscopy for cellular investigations--From single cell imaging to drug carrier uptake visualization. , 2015, Advanced drug delivery reviews.

[69]  J. Pascual,et al.  Canonical and Alternative MAPK Signaling , 2007, Cell cycle.

[70]  J. Schellens,et al.  Current knowledge and future directions of the selective epidermal growth factor receptor inhibitors erlotinib (Tarceva) and gefitinib (Iressa). , 2005, The oncologist.

[71]  D. Bojanic,et al.  Impact of high-throughput screening in biomedical research , 2011, Nature Reviews Drug Discovery.

[72]  C. Kim,et al.  The combination of irreversible EGFR TKIs and SAHA induces apoptosis and autophagy‐mediated cell death to overcome acquired resistance in EGFR T790M‐mutated lung cancer , 2015, International journal of cancer.

[73]  William Pao,et al.  Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers , 2013, Clinical Cancer Research.

[74]  H. Fröhlich,et al.  Activation of AMP-activated protein kinase sensitizes lung cancer cells and H1299 xenografts to erlotinib. , 2014, Lung cancer.

[75]  J. Minna,et al.  Erlotinib hydrochloride , 2005, Nature reviews. Drug discovery.

[76]  P. Jänne,et al.  AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. , 2015, The New England journal of medicine.

[77]  F. J. Ramos,et al.  Anti-epidermal growth factor receptor monoclonal antibodies in cancer treatment. , 2009, Cancer treatment reviews.

[78]  Franck Bonnier,et al.  Evaluation of the potential of Raman microspectroscopy for prediction of chemotherapeutic response to cisplatin in lung adenocarcinoma. , 2010, The Analyst.

[79]  Sara J. Fraser,et al.  Raman imaging of drug delivery systems. , 2015, Advanced drug delivery reviews.

[80]  A. Koloydenko,et al.  Diagnosis of tumors during tissue-conserving surgery with integrated autofluorescence and Raman scattering microscopy , 2013, Proceedings of the National Academy of Sciences.

[81]  Xiao Xu,et al.  The xCELLigence system for real-time and label-free monitoring of cell viability. , 2011, Methods in molecular biology.

[82]  Klaus Gerwert,et al.  In vitro prediction of the efficacy of molecularly targeted cancer therapy by Raman spectral imaging , 2015, Analytical and Bioanalytical Chemistry.

[83]  Hugh J Byrne,et al.  Raman micro spectroscopy study of the interaction of vincristine with A549 cells supported by expression analysis of bcl-2 protein. , 2013, The Analyst.

[84]  C. Sweeney,et al.  The quantification of erlotinib (OSI-774) and OSI-420 in human plasma by liquid chromatography-tandem mass spectrometry. , 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[85]  M. Meyerson,et al.  Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression. , 2005, Cancer research.

[86]  S. Rehman,et al.  Vibrational Spectroscopy for Tissue Analysis , 2012 .

[87]  M. Baccarani,et al.  Second-Generation Tyrosine Kinase Inhibitors: The Future of Frontline CML Therapy , 2011, Clinical Cancer Research.

[88]  P. Johnston,et al.  Cancer drug resistance: an evolving paradigm , 2013, Nature Reviews Cancer.

[89]  I. Oh,et al.  Combining Erlotinib with Cytotoxic Chemotherapy May Overcome Resistance Caused by T790M Mutation of EGFR Gene in Non-Small Cell Lung Carcinoma , 2009 .

[90]  B. Hug,et al.  Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects. , 2011, British journal of clinical pharmacology.

[91]  M. Hidalgo,et al.  Specific method for determination of OSI-774 and its metabolite OSI-420 in human plasma by using liquid chromatography-tandem mass spectrometry. , 2003, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[92]  Peter Kirkpatrick,et al.  Erlotinib hydrochloride , 2005, Nature Reviews Drug Discovery.

[93]  William Pao,et al.  AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. , 2014, Cancer discovery.

[94]  M. Hidalgo,et al.  EGFR inhibitor-mediated apoptosis in solid tumors. , 2007, Journal of experimental therapeutics & oncology.

[95]  Suzanne F. Jones,et al.  A Phase I Study with Neratinib (HKI-272), an Irreversible Pan ErbB Receptor Tyrosine Kinase Inhibitor, in Patients with Solid Tumors , 2009, Clinical Cancer Research.